Michael Santos, Ph.D. | Source | SVP and Chief Population Health Science Officer at Foundation for the Nationa...

Michael Santos, Ph.D.

SVP and Chief Population Health Science Officer at Foundation for the National Institutes of Health
On the record
Represented by:
Share profile 
Bio
Edit

Dr. Santos is Senior Vice President, Science Partnerships, and Chief Population Health Science Officer at the Foundation for the National Institutes of Health (FNIH), and Director of the GeneConvene Global Collaborative. Previously, he was a Deputy Director in the Global Health program of the Bill & Melinda Gates Foundation, where he was involved in setting strategy for programs on malaria, tuberculosis, HIV and other international health priorities. He has also been a Principal at Boston Consulting Group.

Recent Quotes
Sign up to view all

  • "We need to focus on ensuring all patients can benefit." - Dr. Santos commenting in Axios on the cost questions around a new gene therapy for sickle cell disease.

Media
Sign up to view all
  • High-Stakes Decision Making for World-Changing Technologies | Michael Santos | TEDxGreatMills

    Society is confronting multiple novel technologies with the potential to impact entire populations, and new ones are on the horizon. We have important decisions to make that require rigorous and inclusive decision-making models that can be applied on a broad scale to a growing number of emerging challenges. As Senior Vice President and Chief Population Health Sciences Officer for the Foundation for the National Institutes of Health, Mike's focus is on accelerating biomedical discoveries. As part of his work at the FNIH, he's also Director of the GeneConvene Global Collaborative, advancing best practices and informed decision-making for the development of genetic biocontrol technologies. Global health is Mike's passion. Before joining the FNIH, he led programs on malaria, tuberculosis and HIV at the Bill & Melinda Gates Foundation and oversaw projects on global health, energy, and the environment in both the public and private sectors at The Boston Consulting Group. Mike...

    Video
  • New sickle cell gene therapies pose cost and access questions

    Axios article on the FDA approval of a new gene therapy for sickle cell disease

    Article
Employment
Sign up to view all